Did you mean 514 4,5 8?
Displaying drugs 1276 - 1300 of 2038 in total
OM85
OM-85, a bacterial extract, is an immunomodulator of interferon-β production and inflammasome activity.
Investigational
JBI-802
Investigational
VTX-803
Investigational
MK-8777
MK-8777 is under investigation in clinical trial NCT00610649 (Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)).
Investigational
DA-8031
DA-8031 is under investigation in clinical trial NCT01798667 (Clinical Trial to Evaluate the Efficacy and Safety of DA-8031 in Male Patients With Premature Ejaculation).
Investigational
ACG-801
Investigational
9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide
9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide is an inactive derivative of the antitumour agents N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 9-amino-DACA.
Experimental
Minnelide free acid
Investigational
Matched Iupac: … 2-yl)-3,6,10,16-tetraoxaheptacyclo[11.7.0.0^{2,4}.0^{2,9}.0^{5,7}.0^{9,11}.0^{14,18}]icos-14(18)-en-8- …
Sitamaquine
Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of visceral leishmaniasis.
Investigational
Matched Iupac: … N-[6-(diethylamino)hexyl]-6-methoxy-4-methylquinolin-8-amine …
Matched Description: … Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army …
Matched Description: … Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army …
Erzotabart
Erzotabart is under investigation in clinical trial NCT04824794 (GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies).
Investigational
Minnelide
Investigational
Matched Iupac: … 2-yl)-3,6,10,16-tetraoxaheptacyclo[11.7.0.0^{2,4}.0^{2,9}.0^{5,7}.0^{9,11}.0^{14,18}]icos-14(18)-en-8- …
AZD-8330
AZD-8330 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival. AZD-8330 has shown tumor suppressive activity in multiple preclinical models of human cancer including melanoma, pancreatic, colon, lung, and breast cancers.
Investigational
TBAJ-876
Investigational
PTI-801
PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone. It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist.
Investigational
BLX-883
BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C. Alfa interferon is used in the treatment of hepatitis C, hepatitis B, and multiple cancers and its worldwide sales currently exceed $3 billion.
Investigational
REN-850
REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.
Investigational
CHS-828
CHS-828 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
MK-8245
MK-8245 has been used in trials studying the treatment of Type 2 Diabetes Mellitus.
Investigational
MK-8666
MK-8666 is under investigation in clinical trial NCT01971554 (Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)).
Investigational
Matched Iupac: … (2S,3S,4R)-8-{[4'-(3-methanesulfonylpropoxy)-2',6'-dimethyl-[1,1'-biphenyl]-3-yl]methoxy}-9-azatricyclo …
PEN-866
PEN-866 is under investigation in clinical trial NCT03221400 (PEN-866 in Patients With Advanced Solid Malignancies).
Investigational
BBP-812
Investigational
MK-8719
Investigational
AB-8939
Investigational
Displaying drugs 1276 - 1300 of 2038 in total